

Supplementary materials

Table S1 Oncologic and Continence Results

Characteristics	None nerve-sparing	Nerve-sparing	<i>P</i>
Total, n	22	11	
Pathological stage			
No more than T2	21	11	
T3a	1	0	
Lymph node positive	0	0	
Positive surgical margin	1	0	
Number of lymph nodes, n	16	20	
Incidental prostate cancer	1	0	
Day continence			
Within 1 month	0	11/11(100%)	
Within 6 months	8/22 (36.4%)	11/11(100%)	
Within 12 months	20/22 (90.9%)	11/11(100%)	
Night continence			
Within 1 month	3 (3–4)	2 (3–4)	< 0.001
Within 6 months	3 (3–3)	2 (2–2)	< 0.001
Within 12 months	2 (2–2.25)	1 (1–2)	< 0.001
Median bladder capacity(IQR), ml	300 (243.75–300)	350 (300–350)	< 0.001

Note: Day continence was defined by no need of pads. Night continence ability was measured by the count of pads usage.

Table S2 Continence and Erection function results between different nerve-sparing technique

Characteristics	Intrafascial Technique	Interfascial Technique	P
Total, n	5	6	
Age (yr), Mean (Range)	51 (50–56)	55.5(49.8–57.5)	0.647
BMI, Kg/m ² , Mean (Range)	24.8 (23.9–25.4)	24.7 (23.4–26.5)	0.792
Day continence			
Within 1 month	5/5	6/6	
Within 6 months	5/5	6/6	
Within 12 months	5/5	6/6	
Night continence (IQR)			
Within 1 month	3 (2.5–3)	3.5 (3–4)	0.054
Within 6 months	2 (1–2)	2 (2–3)	0.056
Within 12 months	1 (1–1)	2 (1–2)	0.029
Median Bladder capacity	350 (300–350)	300 (300–362.5)	0.609
Median IIEF-6 scores (IQR)			
Preoperative	24 (24–26.5)	24.5 (24–25)	1.000
Within 3 months	20 (20–23)	13.5 (10–16.5)	0.005
Within 9 months	21 (20.5–24)	15.5 (14.75–17.25)	0.006
Within 12 months	23 (22–25)	19 (17.75–20.25)	0.008

Note: All the erection function was assessed without taking Tadalafil.